CCIL scientists improve BRAF inhibitor for better blood brain barrier penetration

Date

07/25/22

Written by CCIL Communications

Urbana, Ill. – Cancers that begin in the brain, or start elsewhere in the body and spread to it, are notoriously difficult to treat. Illinois researchers in Cancer Center at Illinois labs are looking to improve those odds by developing better therapeutics.

The trouble with treating brain tumors is in part due to the blood brain barrier (BBB), which keeps foreign compounds out of the brain via a process called efflux. Briefly, drugs might be able to enter the brain initially, but are pumped out rapidly via efflux transporters such as P-glycoprotein. One such drug includes dabrafenib, a drug that is used to treat cancers including metastatic melanoma by inhibiting BRAF, an oncogene that encodes a protein which plays an important role in cell function.

A recent paper published by CCIL scientists Paul Hergenrother and Timothy Fan studied the features that enable efflux evasion, and attempted to embed those features into dabrafenib, which cannot penetrate the BBB.

Aya M. Kelly (PhD, '22), first author and chemistry graduate student alum from Hergenrother’s lab, led these efforts and developed a new compound, everafenib. Matthew Berry, a student from Fan’s lab, also contributed to the study.

Everafenib evades BBB efflux and the research showed that the new drug is much more successful in treating stereotactically-implanted melanomas in mouse brains, compared to dabrafenib. The team is hopeful that these findings suggest everafenib will also be highly effective in treating metastatic brain melanoma in humans.

“We’re always optimistic about the clinical possibilities, but it’s hard to know. For a basic science paper and team, it’s exciting just to show it is possible to develop a systematic way to get a drug into the brain and treat a cancer.”

— Paul Hergenrother, Kenneth L. Rinehart Jr. Endowed Chair in Natural Products Chemistry, and Professor of Chemistry

Dabrafenib has been used to treat metastatic melanomas in the past, but with low survival rates. Thus far, there has been no alternative; everafenib may provide an opportunity to increase therapeutic efficacy in these difficult-to-treat diseases.

“Tim and I both know that treating brain tumors is a huge challenge – we’ve been working on treating them in pet dogs and are continuing to develop one of our previous compounds for humans. We’ve had a long-standing interest in this desolate landscape, and it leads us to this work – to assess what can work and get into the brain,” Hergenrother said.

Head shot of Aya Kelly on a grey background
Aya Kelly

Everafenib was created after the group found that two chemical features are correlated with the evasion of efflux: the addition of a carboxylic acid group and a lower molecular weight. Everafenib also achieves a higher absolute concentration in the brain, meaning higher concentrations of the drug are retained in the brain, increasing the chances of successfully treating a cancer.

The researchers believe that there is a possibility that these features could also be successful in adapting other compounds to increase their BBB penetrance and efficacy in the brain.

“The discovery of these physical and chemical characteristics that have the potential to open up the door very broadly across different molecules and have anticancer efficacy in brain cancer, but even more broadly to diseases of the central nervous system,” Fan said. “Small molecules that can get in and treat diseases in the brain is the beauty and promise of this research. The possibility of these modifications and our understanding of how molecule size affects efflux broadens our horizons.”

  • The paper, “Target-Agnostic P-Glycoprotein Assessment Yields Strategies to Evade Efflux, Leading to a BRAF Inhibitor with Intracranial Efficacy,” is available online. DOI: 10.1021/jacs.2c03944

Paul Hergenrother is Deputy Director of the Cancer Center at Illinois, and a Professor of Chemistry, and Affiliate in Biochemistry, and the Kenneth L. Rinehart Jr. Endowed Chair in Natural Products Chemistry. Timothy Fan is program leader of the CCIL’s Cancer Discovery Platforms research program and a professor of veterinary clinical medicine.

Related People

hergenro

Directory

scheelinAlexander
Scheeline
bjmccallBenjamin
McCall
r-gennisRobert
Gennis
j-gerltJohn
Gerlt
sgranickSteve
Granick
mgruebelMartin
Gruebele
hergenroPaul
Hergenrother
huangRaven
Huang
mlkraftMary
Kraft
leckbandDeborah
Leckband
yi-luYi
Lu
martinisSusan
Martinis
snairSatish
Nair
eoldfielEric
Oldfield
cmsCharles
Schroeder
zanZaida
Luthey-Schulten
selvinPaul
Selvin
sksScott
Silverman
s-sligarStephen
Sligar
tajkhorsEmad
Tajkhorshid
zhao5Huimin
Zhao
pbraunPaul
Braun
mdburkeMartin
Burke
jeffchanJefferson
Chan
sdenmarkScott
Denmark
dlottDana
Dlott
foutAlison
Fout
agewirthAndrew
Gewirth
ggirolamGregory
Girolami
sohirataSo
Hirata
jainPrashant
Jain
jkatzeneJohn
Katzenellenbogen
nmakriNancy
Makri
douglasmDouglas
Mitchell
jsmooreJeffrey
Moore
murphycjCatherine
Murphy
r-nuzzoRalph
Nuzzo
dimerPhilip
Phillips
rauchfuzThomas
Rauchfuss
joaquinrJoaquín
Rodríguez-López
sarlahDavid
Sarlah
kschweizKenneth
Schweizer
jsweedleJonathan
Sweedler
vddonkWilfred
van der Donk
renskeRenske
van der Veen
vuraweisJosh
Vura-Weis
mcwhite7M.
White
sczimmerSteven
Zimmerman
beakPeter
Beak
wklemperWalter
Klemperer
jdmcdonaJ.
McDonald
pogoreloTaras
Pogorelov
mshen233Mei
Shen
dewoonDavid
Woon
wboulangWilliam
Boulanger
rxbRohit
Bhargava
qchen20Qian
Chen
jianjuncJianjun
Cheng
hy66Hong
Yang
andinomaJosé
Andino Martinez
decosteDonald
DeCoste
thhuangTina
Huang
tjhummelThomas
Hummel
dkellDavid
Kell
doctorkMichael
Koerner
marvilleKelly
Marville
crrayChristian
Ray
tlbrownTheodore
Brown
rmcoatesRobert
Coates
thdjrThom
Dunning
dykstraClifford
Dykstra
j-jonasJiri
Jonas
j-lisyJames
Lisy
shapleyJohn
Shapley
pshapleyPatricia
Shapley
zumdahl2Steven
Zumdahl
ksuslickKenneth
Suslick
jcoxJenny
Cox
sqdSean
Drummond
sheeleySarah
Sheeley
jsmaddenJoseph
Madden
cknight4Connie
Knight
schulzeHeather
Schulze
kbaumgarKeena
Finney
adkssnBeatrice
Adkisson
trabari1Katie
Trabaris
metclfKara
Metcalf
ljohnso2Lori
Johnson
lchenoweLeslie
Chenoweth
wdedoWolali
Dedo
spinnerDavid
Spinner
plblumPatricia
Simpson
stevens2Chad
Stevens
lsagekarLori
Sage-Karlson
bertholdDeborah
Berthold
kecarlsoKathryn
Carlson
sdesmondSerenity
Desmond
axelson2Jordan
Axelson
scbakerStephanie
Baker
pflotschPriscila
Falagan Lotsch
dgrayDanielle
Gray
thennes2Tom
Hennessey
holdaNancy
Holda
aibarrAlejandro
Ibarra
kimshSung Hoon
Kim
kocherg2Nikolai
Kocherginsky
philipk2Philip
Kocheril
legare2Stephanie
Legare
alewandoAgnieszka
Lewandowska
smccombiStuart
McCombie
jdm5Justin
McGlauchlen
egmooreEdwin
Moore
myerscouKathleen
Myerscough
snalla2Siva
Nalla
romanovaElena
Romanova
roubakhiStanislav
Rubakhin
shvedalxAlexander
Shved
asoudaAlexander
Soudakov
xywangXiying
Wang
kwilhelKaren
Wilhelmsen
wilkeyRandy
Wilkey
silongSilong
Zhang
schlembaMary
Schlembach
trimmellAshley
Trimmell
emccarr2Elise
McCarren
cmercierChristen
Mercier
atimpermAaron
Timperman
niesShuming
Nie
hshanHee-Sun
Han
mmgMutha
Gunasekera
kknightsKatriena
Knights
lisawLisa
Williamson
keinckKatie
Einck
kneef1Kate
Neef
txiang4Tiange
Xiang
j-hummelJohn
Hummel
i-paulIain
Paul
munjanjaLloyd
Munjanja
glnGayle
Nelsen
agerardAnna
Gerard
powerskaKimberly
Powers
lolshansLisa
Olshansky
miricaLiviu
Mirica
qingcao2Qing
Cao
lisa3Lisa
Johnson
tinalambTina
Lamb
baronpBaron
Peters
bransle2Sarah
Bransley
dylanmh2Dylan
Hamilton
raegansRaegan
Smith
apm8Angad
Mehta
leverittJohn
Leveritt
xingwXing
Wang
emillrEva
Miller
jmill24Jacqueline
Miller
jlbass2Julia
Bass
ramonarRamona
Rudzinski
tlcraneTracy
Crane
cejohnstCelia
Johnston
adlAmber
LaBau
cnsolomoCandice
Solomon-Strutz
mikaelbMikael
Backlund
jacksonnNick
Jackson